What we have learned about cachexia in gastrointestinal cancer

被引:69
作者
Palesty, JA [1 ]
Dudrick, SJ [1 ]
机构
[1] Yale Univ, St Marys Hosp, Dept Surg, Waterbury, CT 06706 USA
关键词
cancer; cachexia; cancer cachexia syndrome; malnutrition; anorexia; gastrointestinal cancer;
D O I
10.1159/000073337
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
It is appreciated widely by clinicians that significant malnutrition accompanies malignant processes in approximately 50% of patients and eventually leads to severe wasting which accounts for approximately 30% of cancer-related deaths overall, 30-50% of deaths in patients with gastrointestinal tract cancers, and up to 80% of deaths in patients with advanced pancreatic cancer. The body wasting known as cancer cachexia is a complex syndrome characterized by progressive tissue depletion and decreased nutrient intake that is manifested clinically as inexplicable, recalcitrant anorexia and inexorable host weight loss. Decreased nutritional intake, increased metabolic expenditure and dysfunctional metabolic processes, including hormonal and cytokine-related abnormalities, all appear to play roles in the development of cancer cachexia. Although this condition of advanced protein-calorie malnutrition, sometimes described as the cancer anorexia-cachexia syndrome, is not entirely understood, it appears to be multifactorial, is a major cause of morbidity and mortality in cancer patients, and ultimately leads to death. Therapeutic interventions have met with little success, and, regardless of tremendous efforts throughout the decades, the exact nature of the mediators responsible for cancer cachexia remain elusive. The pathogenesis of cancer cachexia appears to be related to proinflammatory cytokines, alterations in the neuroendocrine axis and tumor-derived catabolic factors. Despite trials of conventional and/or aggressive nutritional support by a myriad of feeding techniques, patients with cancer cachexia have failed to gain consistent significant benefits in terms of weight gain, functional ability, quality of life or survival. Additionally, attempts to ameliorate the abnormal clinical and metabolic features of cancer cachexia with a variety of pharmacologic agents have met with only limited success. Either until cancer of the gastrointestinal tract can be cured or until it is possible to identify the exact causes and mechanisms of the cancer cachexia syndrome, the most realistic and practical options currently are directed toward minimizing adverse gastrointestinal side effects or complications of the malignant process and/or therapy, as well as increasing appetite, food intake and nutrient utilization in an effort to enhance quality of life and improve survival. Copyright (C) 2003 S. Karger AG, Basel.
引用
收藏
页码:198 / 213
页数:16
相关论文
共 162 条
[51]  
Fainsinger R L, 1993, J Palliat Care, V9, P4
[52]   USEFULNESS OF MEGESTROL-ACETATE IN CANCER CACHEXIA AND ANOREXIA - A PLACEBO-CONTROLLED STUDY [J].
FELIU, J ;
GONZALEZBARON, M ;
BERROCAL, A ;
ARTAL, A ;
ORDONEZ, A ;
GARRIDO, P ;
ZAMORA, P ;
DEPAREDES, MLG ;
MONTERO, JM .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (05) :436-440
[53]   Supportive use of megestrol acetate in patients with head and neck cancer during radio(chemo)therapy [J].
Fietkau, R ;
Riepl, M ;
Kettner, H ;
Hinke, A ;
Sauer, R .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (01) :75-79
[54]   What's in a name? In search of leptin's physiologic role [J].
Flier, JS .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1998, 83 (05) :1407-1413
[55]   THE EFFECT OF ANABOLIC-STEROIDS ON LEAN BODY-MASS - THE DOSE-RESPONSE CURVE [J].
FORBES, GB .
METABOLISM-CLINICAL AND EXPERIMENTAL, 1985, 34 (06) :571-573
[56]   Leptin and the regulation of body weight in mammals [J].
Friedman, JM ;
Halaas, JL .
NATURE, 1998, 395 (6704) :763-770
[57]   Peptidergic regulation of gastrointestinal motility in rodents [J].
Fujimiya, M ;
Inui, A .
PEPTIDES, 2000, 21 (10) :1565-1582
[58]   A review of the drug treatment of cachexia associated with cancer [J].
Gagnon, B ;
Bruera, E .
DRUGS, 1998, 55 (05) :675-688
[59]  
GELIN J, 1991, CANCER RES, V51, P415
[60]   A receptor subtype involved in neuropeptide-Y-induced food intake [J].
Gerald, C ;
Walker, MW ;
Criscione, L ;
Gustafson, EL ;
BatzlHartmann, C ;
Smith, KE ;
Vaysse, P ;
Durkin, MM ;
Laz, TM ;
Linemeyer, DL ;
Schaffhauser, AO ;
Whitebread, S ;
Hofbauer, KG ;
Taber, RI ;
Branchek, TA ;
Weinshank, RL .
NATURE, 1996, 382 (6587) :168-171